# A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

> **NCT02214121** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

## Interventions

- **DRUG:** Ticagrelor Dose 1a + Dose 2a
- **DRUG:** Ticagrelor Dose 1b + Dose 2b

## Key facts

- **NCT ID:** NCT02214121
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-11
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214121, "A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02214121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*